Investment Q&A

Q: hi. in regards these pipelines: 1) how much are these stocks dependent on the price of oil, on the volumes of oil through their pipes, and where that oil is being shipped from (eg Canada) to ( eg Canada or the US ). 2) do these stocks need growth in the tar sands for their growth? 3) how long a runway do they have with our weaning off oil?

Q: In your response to Leonard today regarding the potential CSU spinout of Topicus you mentioned that CSU shares will likely drop to reflect the value of the spin out. Does that imply that shareholders of CSU would receive shares of Topicua? Thank you.

Q: Thoughts on skrr appreciated.Thanks.

Q: Can you make a case for or against owning Neorocrine Biosciences? I have read a case to buy from another service and would value your take on it. How are the fundamentals and pipeline? Any ideas on why it has recently pulled back?

Q: I would appreciate an update on your views about VMO. In the past, you have indicated support for the momentum factor strategy, but recommended that investors avoid ETFs with less than $100M in AUM. Given that VMO has an inception date of June 2016 and only $29M in AUM to date, do you still see this ETF as a good investment or is there another international momentum ETF which you prefer? Also, would this ETF be appropriate for a TFSA account?

Thank you for your insightful advice.

Q: What comparable US company would you recommend in this sector? Is there an ETF for healthcare in general that you prefer?

Q: What is a tsx listed equivilent ? Thanks.

Q: I was wondering if you could provide any comments on Relay Medical. I have read that they are involved in rapid testing for COVID-19. I would appreciate any insight you may have to offer. Thanks so much!

Q: Hi,

I'm not sure what to make of the announcement of QUIS hiring an outside company (Gateway) to help them with investor relations. Is it positive because Gateway will be able to increase QUIS visibility to institutional investors? Is it negative in that QUIS may be desperate and needs assistance? ...or is it a non-issue?

Thanks as always for your valuable insight.

Q: As per my portfolio analysis I have reduced my position in tech and industrial. One area Where I don’t have an investment I.e. communication services I’ve taken A partial position in BCE. I need to add health care. What is your opinion of the above? What would be your top pick in this area.

Q: 5i, Upcoming IPOs, Palantir and Nuvei, I like to invest in one, 3 - 5 years hold, do you favor one over the other ?
Thanks

Q: With the purchase of Arms is NVDA a good stock to keep holding?? Do you see any downside. Does the purchase put it in the high debt bracket or is it very beneficial to NVDA in which case it doesn't matter that much.

Thanks for everything.

Q: The company announced a debenture financing at 6.5% today to pay out a convertible debenture that only cost 5.5% and does not mature until Dec/21. The proposed debenture does not mature until Dec/20025. Is it fair to surmise that the company was prepared to pay a higher interest rate to get a longer maturity and to remove the possibility that the current debentures might be converted to shares because it believes the share price may in fact increase above the $8.35 conversion price?

Q: Hi, Any insight into pricing of 1.1 miliion shares secondary of common shares and $800mln convertible notes offering by Shopify ? Thanks

Q: Hi Peter and Team,

Freegold ventures is getting creamed after their release of drill results. Are the drill results really THAT bad?

Thanks,

Marc

Q: Two part question about CSU: some time ago there was an announcement of a transaction where a company acquired by CSU would be "spun out" to CSU shareholders. Can you provide details of what is to happen? when is it to happen? do you expect CSU's share price to decrease as a result? What tax consequence will there be to CSU shareholders?
Secondly, I recently read the following:
"Our Strong Sell is based on our conviction that it
is difficult to create shareholder value by
continuing to add shrinking legacy software
businesses to 100’s of other shrinking legacy
software businesses. With organic topline
contraction and fading operating leverage, we
see CSU’s “never-ending roll-up” finally hitting
hard limits. In our view, CSU is too reliant on the
assumption of customer stickiness for legacy
apps with expensive support contracts in
dozens of niche/vertical markets. We see these
apps increasingly dislodged by less expensive,
more inherently agile, cloud alternatives. A
Covid-19-driven economic downturn would
likely intensify this competition, as it is our
experience that, rather than preserving the
status quo, tough times drive customers to
overcome inertia and accelerate paradigm
shifts in enterprise IT."
What is your assessment of this?
Thank you for your excellent service.

Q: Can you tell me why this stock is drifting down Is it a buy hold or sell and reason it is Thanks

Q: I currently own GIB.A. While I’ve been not unhappy with the company I’m wondering what your thoughts would be on switching to Microsoft. Would there be a similar potential for gain and a reduced risk level while owning a much larger company?
Thank you for your fantastic service.
Mike

Q: Is USA worth holding, seems like its continually being out performed by its peer's. I have positions in BTO, FMV, AEM, KL, MMX (10% of portfolio combined). Perhaps a USA sale and top up of KL which is only a 1.34% weighting. Do like the Silver exposure with USA and was looking at MAG which seems to outperform USA.

Q: hi team, would you consider the ev sector is another boom n bust Mary j （weed)